Navigation Links
Actavis Receives Approval of Bupropion HCl SR 100mg and 200mg in the U.S.
Date:7/21/2010

MORRISTOWN, N.J., July 21 /PRNewswire/ -- Actavis Group, the international generic pharmaceuticals company, today announced that it has received approval from the U.S. Food & Drug Administration to market Bupropion HCl Extended-Release (SR) tablets 100mg and 200mg.  Distribution of the product will commence immediately.  

Bupropion HCl SR Tablets, the generic equivalent of Wellbutrin® SR by GlaxoSmithKline, are now available from Actavis in the following strengths: 100mg, 150mg, and 200mg.  Bupropion HCl SR is used in the treatment of major depressive disorder.  Annual U.S. sales of Wellbutrin® SR 100mg and 200mg and the generic equivalent in that strength was US$115 million for the 12 months ending March 2010 according to IMS Health data. The addition of the 100mg and 200mg Bupropion HCl SR complements Actavis' already approved and marketed Bupropion HCl SR 150mg. Actavis received approval of Bupropion HCl SR 150mg in March, 2008.  

Commenting on the new approval, Michael Perfetto, Vice President of Sales & Marketing in the United States said:

"The approval of Bupropion SR 100mg and 200mg allows Actavis to provide the full range of strengths available on both Bupropion SR and XL products and offers a significant value to our customers and patients.  This approval also underscores Actavis' emphasis and commitment to bringing complex controlled-release products to the marketplace."

About Actavis Inc.

Actavis Inc. is the U.S. subsidiary of Actavis Group hf. Approximately one third of Actavis' sales are generated in North America, Actavis' single largest market. Based in Morristown, NJ, Actavis has U.S. manufacturing facilities in Elizabeth, NJ and Lincolnton, NC. Actavis also has research and development facilities in Owings Mills, MD and Sunrise, FL.

About Actavis Group

Actavis is one of the world's leading generic pharmaceutical companies specializing in the development, manufacture and sale of generic pharmaceuticals.  The company has operations in 40 countries, with more than 10,500 employees.

Information in this press release may contain forward-looking statements with respect to the financial condition, results of operations and businesses of Actavis.  By their nature, forward-looking statements and forecasts involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from that expressed or implied by these forward-looking statements. These factors include, among other things, exchange rate fluctuations, the risk that research and development will not yield new products that achieve commercial success, the impact of competition, price controls and price reductions, the risk of loss or expiration of patents or trade marks, difficulties of obtaining and maintaining governmental approvals for products, the risk of substantial product liability claims, exposure to environmental liability.


'/>"/>
SOURCE Actavis Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Actavis Receives Approval of Alprazolam ODT in the U.S.
2. Actavis Launches Generic Version of Flomax(R) In The U.S.
3. Sagent Pharmaceuticals and Actavis Enter Into Exclusive U.S. Development, Supply and Marketing Collaboration for a Portfolio of Specialty Injectable Pharmaceutical Products
4. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
5. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
8. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
9. CryoCor Receives FDA Approval for Right Atrial Flutter
10. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
11. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... , April 19, 2017  Novartis today ... the National Heart, Lung, and Blood Institute (NHLBI) ... that 58% of patients with treatment-naïve severe aplastic ... when treated with eltrombopag at the initiation of ... The study evaluated three sequential treatment groups, or ...
(Date:4/18/2017)... 2017  Cardinal Health (NYSE: CAH ) ... earnings per share (EPS) guidance and providing a preliminary ... conjunction with this morning,s announcement of the planned acquisition ... Insufficiency businesses. Cardinal Health now believes that ... at the bottom of its previous guidance range of ...
(Date:4/18/2017)... DALLAS , April 18, 2017 Viverae ... proud to announce the integration of IBM ® ... platform to deliver targeted communications for a personalized experience. ... meaningful actions on their health in real time. The ... that matter most to members, wherever they are in ...
Breaking Medicine Technology:
(Date:4/24/2017)... RICHEY, Fla. (PRWEB) , ... April 24, 2017 ... ... and Prevention (CDC), rising prescription opioid overdose deaths now claim the lives of ... slashed its civil case filings against drug manufacturers, distributors, pharmacies and prescribers by ...
(Date:4/24/2017)... ... April 24, 2017 , ... MAP Health Management announced ... in people with addiction who are served by MAP’s patient engagement ecosystem. Lief ... that monitors heart and breath rates to identify anxiety levels and can provide ...
(Date:4/24/2017)... ... April 24, 2017 , ... Pitavastatin, a relatively new statin, ... not known to have significant interactions with antiretroviral therapy (ART). Among people ... and dampen inflammation in the bloodstream. , While lowering cholesterol and dampening inflammation ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... Come to ... Hotel, 4200 Jim Walter Blvd, for an educational and exciting 2-day program. , ... our staff hearing this before they approach patients” about the course entitled Ain't Misbehavin': ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... Donna Parker, ... but she has not found any of them to be very practical. She wanted ... slowly and easily make changes in their health. It prompted her in writing “ ...
Breaking Medicine News(10 mins):